Fig. 6: UBA6 in tumour cells predicts patient outcomes to immunotherapy.
From: Inhibition of UBA6 by inosine augments tumour immunogenicity and responses
a The association between CTL and OS of melanoma patients with distinct UBA6 levels. b Kaplan–Meier plots of PFS of melanoma patients with anti-CTLA4 (n = 42) and OS of melanoma patients with anti-PD1 (n = 47) based on UBA6 level. c Representative UBA6 protein staining tumour sections (top: 100×, bottom: 400×) (left) and CT scans (right) of lung cancer patients with anti-PD1 treatment. CT scans of tumours (top) and mediastinal lymph nodes (bottom) of patient 1 and left pleural effusion (top) and pericardial effusion (bottom) of patient 2 are highlighted by red arrows. Data were representative of three independent experiments (n = 3). d Waterfall plot depicting the responses to anti-PD1 treatment by the best change in the sum of target lesions, in comparison to baseline, in cancer patients with low UBA6 (n = 16) or high UBA expression (n = 6). Every bar represents one patient and the colours correspond to response to anti-PD1 treatment (PR partial response, SD stable disease, PD progressive disease). Dotted black lines indicate the response as described by RECIST1.1. e Pie charts of response fractions for each group of patients with UBA6-low and UBA6-high expression in tumour cells. Data are presented as Mean ± s.e.m. Statistical significance was determined by a log-rank test (a, b). Source data are provided as a Source Data file.
